What is Roth Capital’s Forecast for TENX FY2024 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Roth Capital upped their FY2024 earnings estimates for Tenax Therapeutics in a research report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff now expects that the specialty pharmaceutical company will post earnings per share of ($1.16) for the year, up from their prior estimate of ($6.01). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $1.82 EPS and FY2028 earnings at $3.08 EPS.

A number of other equities analysts also recently weighed in on TENX. Guggenheim started coverage on shares of Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 target price for the company. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. Leerink Partners assumed coverage on shares of Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price for the company. William Blair assumed coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock. Finally, StockNews.com assumed coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Down 0.8 %

Shares of NASDAQ TENX opened at $4.83 on Monday. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $33.44. The company has a 50 day simple moving average of $4.02 and a two-hundred day simple moving average of $3.70.

Institutional Investors Weigh In On Tenax Therapeutics

A number of institutional investors have recently made changes to their positions in TENX. Sphera Funds Management LTD. purchased a new stake in shares of Tenax Therapeutics during the third quarter valued at approximately $101,000. Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics in the third quarter worth approximately $173,000. Finally, Vestal Point Capital LP purchased a new stake in Tenax Therapeutics in the third quarter worth approximately $288,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.